Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge?
John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.
Cancer death rate dropping 1.1 percent a year, annual report finds.
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Insights from ASCO 2025: Real-world evidence drives clinical decision-making